Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Cash & Current Investments (2016 - 2025)

Voyager Therapeutics' Cash & Current Investments history spans 11 years, with the latest figure at $196.4 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 26.34% year-over-year to $196.4 million; the TTM value through Dec 2025 reached $196.4 million, down 26.34%, while the annual FY2025 figure was $196.4 million, 26.34% down from the prior year.
  • Cash & Current Investments for Q4 2025 was $196.4 million at Voyager Therapeutics, up from $163.8 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $371.0 million in Q2 2024 and bottomed at $34.8 million in Q3 2022.
  • The 5-year median for Cash & Current Investments is $192.1 million (2023), against an average of $192.6 million.
  • The largest annual shift saw Cash & Current Investments tumbled 71.38% in 2022 before it surged 439.61% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $132.5 million in 2021, then fell by 10.33% to $118.8 million in 2022, then soared by 94.26% to $230.9 million in 2023, then grew by 15.51% to $266.7 million in 2024, then fell by 26.34% to $196.4 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Cash & Current Investments are $196.4 million (Q4 2025), $163.8 million (Q3 2025), and $215.6 million (Q2 2025).